statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. stocks rose on Friday morning as investors digested the latest inflation data, which reinforced expectations of a September interest rate cut. The broader market exhibited a mixed performance in the previous session, with early optimism stemming from strong GDP data fading as tech giants dragged down the Nasdaq and S&amp;P 500.Here’s a look at the top three stocks that captured retail investors’ attention ahead of the opening bell today:Windtree Therapeutics Inc (WINT)<figure class="image"><a href="https://stocktwits.com/symbol/WINT"><img style="aspect-ratio:1316/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WINT_sentiment_and_message_volume_score_on_Jul_26_58f5cea25d.png" alt="WINT sentiment and message volume score on Jul 26.png" width="1316" height="320"></a><figcaption>WINT sentiment and message volume score premarket on Jul 26</figcaption></figure>Shares of Windtree Therapeutics surged by an impressive 150% in pre-market trading to reach a high $9.40. The biopharma company announced an update on its novel heart failure treatment, istaroxime, igniting a buying frenzy among retail investors.&nbsp;Stocktwits data revealed overwhelmingly bullish sentiment (71/100), with message volume reaching its highest level this year (90/100). While the stock has experienced a significant decline of over 73% year-to-date, today's surge has injected a dose of optimism among investors.Dexcom Inc (DXCM)In stark contrast to Windtree's performance, Dexcom Inc witnessed a dramatic decline of over 36% in pre-market trading, settling in the mid $60s. The medical device company's disappointing second-quarter revenue results and a weak FY24 revenue guidance for its glucose monitoring devices triggered a sell-off. Despite the price drop, several analysts maintained price targets well above current levels, suggesting potential upside in the long term.&nbsp;However, retail investor sentiment on Stocktwits plummeted to its lowest point this year (10/100), reflecting the bearish outlook, while message volumes reached a 2024 peak (96/100). Concerns about management’s inability to adequately communicate business issues and its plan to fix it, as well as market share impacts from the adoption of GLP-1 weight loss drugs is keeping retail away. &nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:1324/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DXCM_sentiment_and_message_volume_score_on_Jul_26_17d563e160.png" alt="DXCM sentiment and message volume score on Jul 26.png" width="1324" height="314"></a><figcaption>DXCM sentiment and message volume score premarket on Jul 26</figcaption></figure>Anavex Life Sciences Corporation (AVXL)Shares of Anavex Life Sciences Corporation climbed over 4% in pre-market trading to a high of $7.22, with retail sentiment on Stocktwits at bullish levels (65/100).&nbsp;The neuro-disease-focused biopharma company received a boost from EF Hutton analyst Jason Kolbert, who initiated coverage with a Buy rating and a price target of $46. The analyst highlighted the company's lead therapy, ANAVEX2-73, for Alzheimer's Disease (AD), which is on track for regulatory submission by the end of the year. The potential market for ANAVEX2-73, coupled with its broader therapeutic applications, has fueled investor optimism.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_sentiment_and_message_volume_score_on_Jul_26_d22a8e0bab.png" alt="AVXL sentiment and message volume score on Jul 26.png" width="1320" height="312"></a><figcaption>AVXL sentiment and message volume score premarket on Jul 26</figcaption></figure><a href="https://www.vecteezy.com/photo/29286690-ai-generative-business-man-standing-in-the-stock-market-realistic-image-ultra-hd-high-design-very-detailed">Photo</a> courtesy of syedqaseem on Vecteezy

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Before the Bell

Two stocks are sparking optimism on Stocktwits with watchers passionately discussing potential catalysts, while one is losing a lot of favor following its disappointing earnings and outlook. 

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Premarket

Equity

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More Shareholders that lost money on Anavex Life Sciences...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Anavex Life...

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex PR Newswire NEW...

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More Shareholders that lost money on Anavex Life Sciences...

BERGER MONTAGUE PC ANNOUNCES THE FILING OF A CLASS ACTION COMPLAINT TO RECOVER LOSSES FOR INVESTORS WHO PURCHASED ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL)

BERGER MONTAGUE PC ANNOUNCES THE FILING OF A CLASS ACTION COMPLAINT TO RECOVER LOSSES FOR INVESTORS WHO PURCHASED ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) BERGER MONTAGUE PC ANNOUNCES THE...

Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - AVXL

Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - AVXL Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages...

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders The Gross Law Firm Announces the Filing of a Securities Class...

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit PR Newswire LOS...

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Volume	1.37M
52-Wk High	$10.45
52-Wk Low	$3.25

AVXL Anavex Life Sciences Corporation

About

Feed

News

Sentiment

Earnings

Fundamentals